PGNY Progyny
- 27.080
- -0.470-1.71%
Progyny News
Progyny Is Maintained at Buy by Truist Securities
Progyny Is Maintained at Buy by Truist Securities
Truist Securities: Maintaining the Progyny (PGNY.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $46.00 to $37.00.
Truist Securities: Maintaining the Progyny (PGNY.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $46.00 to $37.00.
Truist Securities Cuts Price Target on Progyny to $37 From $46, Keeps Buy Rating
Progyny (PGNY) has an average rating of buy and price targets ranging from $30 to $48, according to analysts polled by Capital IQ. Price: 27.15, Change: -0.40, Percent Change: -1.45
Progyny Price Target Maintained With a $48.00/Share by Cantor Fitzgerald
Progyny Price Target Maintained With a $48.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight on Progyny, Maintains $48 Price Target
Cantor Fitzgerald analyst Sarah James reiterates Progyny (NASDAQ:PGNY) with a Overweight and maintains $48 price target.
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Arvinas Holding Company (ARVN) and Progyny (PGNY)
Progyny, Inc. to Present at BofA Securities 2024 Healthcare Conference and Leerink Partners Healthcare Crossroads Conference 2024
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Progyny's executives will participate in a
Analysts' Top Healthcare Picks: Xenon (XENE), Progyny (PGNY)
Progyny Price Target Cut to $30.00/Share From $48.00 by Barclays
Progyny Price Target Cut to $30.00/Share From $48.00 by Barclays
Progyny Is Maintained at Overweight by Barclays
Progyny Is Maintained at Overweight by Barclays
Barclays Maintains Overweight on Progyny, Lowers Price Target to $30
Barclays analyst Sarah James maintains Progyny (NASDAQ:PGNY) with a Overweight and lowers the price target from $48 to $30.
Progyny (NASDAQ:PGNY) Has More To Do To Multiply In Value Going Forward
Analysts Conflicted on These Healthcare Names: Insulet (PODD) and Progyny (PGNY)
Fertility Solutions-Focused Progyny Stock Sinks After Soft Guidance; Analyst Says 'Can No Longer Underwrite Sustained Healthy Growth In Forecasts'
On Thursday, Progyny Inc (NASDAQ:PGNY) reported first-quarter sales of $278.1 million, up 7.6% year over year, missing the consensus of $289.46 million, primarily due to the increased number of client
Progyny Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 37.96% Canaccord Genuity $46 → $37 Maintains Buy 05/10/2024 52.87% BTIG $50 → $41 Maintains Buy
Top Midday Decliners
MacroGenics (MGNX) plummeted past 75% amid heavy trading after the company said five patients died in an ongoing mid-stage study of its experimental drug to treat a type of prostate cancer. BMO downgr
Progyny Inc (PGNY) Q1 2024 Earnings: Mixed Results Amid Market Challenges
Progyny Price Target Cut to $41.00/Share From $50.00 by BTIG
Progyny Price Target Cut to $41.00/Share From $50.00 by BTIG
Progyny Is Maintained at Buy by BTIG
Progyny Is Maintained at Buy by BTIG
BTIG: Maintaining the Progyny (PGNY.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $50.00 to $41.00.
BTIG: Maintaining the Progyny (PGNY.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $50.00 to $41.00.
Analysis
Price Target
No Data
